Format

Send to

Choose Destination
MAbs. 2015;7(1):9-14. doi: 10.4161/19420862.2015.989042.

The therapeutic monoclonal antibody market.

Author information

1
a BioProcess Technology Consultants, Inc. ; Woburn , MA USA.

Abstract

Since the commercialization of the first therapeutic monoclonal antibody product in 1986, this class of biopharmaceutical products has grown significantly so that, as of November 10, 2014, forty-seven monoclonal antibody products have been approved in the US or Europe for the treatment of a variety of diseases, and many of these products have also been approved for other global markets. At the current approval rate of ∼ four new products per year, ∼ 70 monoclonal antibody products will be on the market by 2020, and combined world-wide sales will be nearly $125 billion.

PMID:
25529996
PMCID:
PMC4622599
DOI:
10.4161/19420862.2015.989042
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center